NTRK2 and non-small cell lung carcinoma: Given the significant survival benefit obtained from targeted therapies in NSCLC patients with ALK, ROS1, RET, NTRK1, NTRK2 and NTRK3 gene rearrangements, the identification of these patients should be more and more comprehensive, cost-effective and time-efficient.